Role of intratumoral heterogeneity in metastatic progression and drug resistance
Open Access
- 18 September 2025
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-28
Abstract
Metastatic cancer is the final frontier in disease progression with few avenues of treatment open to patients. The failure of therapeutic options at the end-stage disease is confounded by the presence of diverse clones in the metastatic tumor which contributes to intratumoral heterogeneity (ITH), resulting in intrinsic and acquired drug resistance. We aim to elucidate the contribution of ITH to the development of metastasis with a focus on the origins and molecular mechanisms driving ITH, as well as the clinical and technical challenges of acquiring and studying metastatic cohorts in which we can investigate this phenomenon. Bioinformatic approaches that could help in silico analysis will be discussed, which could shed light on how to design new therapeutic strategies for metastatic cancer and give hope to patients living under the shadow of the sword of Damocles.Keywords
All Related Versions
This publication has 116 references indexed in Scilit:
- Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancerNature Communications, 2017
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seqScience, 2016
- Intra-tumor heterogeneity of cancer cells and its implications for cancer treatmentActa Pharmacologica Sinica, 2015
- Whole Genome Sequence Analysis Suggests Intratumoral Heterogeneity in Dissemination of Breast Cancer to Lymph NodesPLOS ONE, 2014
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitorNature, 2014
- Tumor Heterogeneity at Protein Level as an Independent Prognostic Factor in Endometrial CancerTranslational Oncology, 2014
- “Drug resistance associated membrane proteinsâ€Frontiers in Physiology, 2014
- Addressing Genetic Tumor Heterogeneity through Computationally Predictive Combination TherapyCancer Discovery, 2014
- Efflux pump-mediated resistance in chemotherapyAnnals of Medical and Health Sciences Research, 2012
- The Clonal Evolution of Tumor Cell PopulationsScience, 1976